when the leading statement from the CEO is "The excellent safety profile of Xanamem was again demonstrated” it’s time to run.
- Forums
- ASX - By Stock
- Ann: ACW XanaCIDD phase 2a trial topline results
when the leading statement from the CEO is "The excellent safety...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
2.8¢ |
Change
-0.003(9.68%) |
Mkt cap ! $75.92M |
Open | High | Low | Value | Volume |
3.0¢ | 3.1¢ | 2.7¢ | $694.8K | 24.39M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 425457 | 2.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.9¢ | 1277808 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 4199822 | 0.027 |
14 | 1882588 | 0.026 |
23 | 4543643 | 0.025 |
10 | 2745804 | 0.024 |
5 | 384000 | 0.023 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 969361 | 8 |
0.029 | 1253808 | 7 |
0.030 | 3798038 | 18 |
0.031 | 2721835 | 8 |
0.032 | 1231622 | 7 |
Last trade - 14.55pm 13/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online